D. E. Shaw & Co., Inc. Design Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 446,190 shares of DSGN stock, worth $1.49 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
446,190
Previous 290,628
53.53%
Holding current value
$1.49 Million
Previous $770,000
133.51%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding DSGN
# of Institutions
95Shares Held
30.5MCall Options Held
100Put Options Held
100-
Sr One Capital Management, LP6.53MShares$21.9 Million8.85% of portfolio
-
Logos Global Management LP San Francisco, CA5.03MShares$16.9 Million1.89% of portfolio
-
Black Rock Inc. New York, NY2.27MShares$7.62 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.66MShares$5.57 Million0.08% of portfolio
-
Tang Capital Management LLC San Diego, CA1.48MShares$4.96 Million0.73% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $187M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...